Skip Navigation


European Heart Journal Advance Access originally published online on January 27, 2006
European Heart Journal 2006 27(5):506-507; doi:10.1093/eurheartj/ehi693
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/5/506    most recent
ehi693v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lindsey, M. L.
Right arrow Articles by Freeman, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindsey, M. L.
Right arrow Articles by Freeman, G. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

ß-Blockade in heart failure: adding SENIORS to the mix

Merry L. Lindsey* and Gregory L. Freeman

Department of Medicine and Cardiology, University of Texas Health Science Center, 7703 Floyd Curl Drive, Mail Code 7872, San Antonio, TX 78229-3900, USA

* Corresponding author. Tel: +1 210 567 4673; fax: +1 210 567 6960. E-mail address: lindseym@uthscsa.edu

This editorial refers to ‘Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy’{dagger} by S. Ghio et al., on page 562

The first 10% of the full text of this article appears below.

In early 2005, results of the SENIORS trial, a Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure was published.1,2 A total of 2128 patients over the age of 70 were randomized to receive either nebivolol or placebo for a mean follow-up time of 21 months. Nebivolol is a third generation highly selective ß1-adrenergic receptor inhibitor with vasodilator properties mediated through nitric oxide release. Treatment with this agent decreased all-cause mortality or cardiovascular hospitalization (P=0.04). Although previous studies using ß-blockers (bisoprolol, carvedilol, or metroprolol) demonstrated a decreased relative risk of death in heart failure,3 they enrolled . . . [Full Text of this Article]

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy
Stefano Ghio, Giulia Magrini, Alessandra Serio, Catherine Klersy, Alessandro Fucilli, Aleksandr Ronaszèki, Pal Karpati, Giacomo Mordenti, Angela Capriati, Philip A. Poole-Wilson, Luigi Tavazzi, and on behalf of the SENIORS investigators
EHJ 2006 27: 562-568. [Abstract] [Full Text]